Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 153 |
| Active Pipeline (Recruiting Now) | 66 (28) |
| Completed vs Stopped Early | 56 / 31 (20.3%) |
| Median Closed Actual Enrollment | 214 participants |
| Physical Hospital Site Disclosure | 95.7% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 44 (17 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Seoul National University Hospital | Seoul | 34 |
| Severance Hospital, Yonsei University Health System | Seoul, Other | 33 |
| National Taiwan University Hospital | Taipei | 32 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06747949 | A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) | Phase III | RECRUITING |
| NCT07213674 | A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant | Phase III | RECRUITING |
| NCT05549258 | Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder | Phase II | RECRUITING |
| NCT04804553 | Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis | Phase III | RECRUITING |
| NCT03633708 | A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis | Phase III | RECRUITING |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Amgen across sibling Meru public-data platforms.
Explore interactive annual charts and M&A subsidiary rollups in the Amgen Interactive Dossier, benchmark peers in Immunology, Rheumatology, and Dermatology, or review the Healthcare Price & Patent Cliff Crosswalk.